Related Experiment Video
Updated: Jul 19, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
The medical management of opioid dependence in HIV primary care settings
Paula J Lum1, Jacqueline Peterson Tulsky
1Positive Health Program, Department of Medicine, University of California, San Francisco General Hospital, CA 94110, USA. plum@php.ucsf.edu
Abstract:
Injecting drug use is a common mode of transmission among persons with HIV/AIDS. Many HIV-infected patients meet diagnostic criteria for opioid dependence, a chronic and relapsing brain disorder. Most HIV providers, however, receive little training in substance use disorders. Opioid agonist therapy (OAT) has a stabilizing effect on opioid-dependent patients and is associated with greater acceptance of antiretroviral (ARV) therapy, higher ARV adherence, and greater engagement in HIV-related health care. Although methadone maintenance has been the OAT gold standard, methadone is available for the treatment of opioid dependence only in strictly regulated narcotic treatment programs. Buprenorphine, a partial opioid agonist approved for the office-based treatment of opioid dependence in 2002, may result in better health and substance use treatment outcomes for patients with HIV disease.
Related Concept Videos
Analgesia and Pain Management
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Drug Dependence
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Opioid Analgesics: Morphine and Other Natural Cogeners
Retrovirus Life Cycles

